Biogen’s kidney transplant rejection candidate gets FDA breakthrough designation
peterschreiber.media Biogen (NASDAQ:BIIB) has obtained U.S. FDA breakthrough remedy designation for felzartamab, its candidate being developed to deal with antibody-mediated ...
